Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma
Open Access
- 22 April 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 92-100
Abstract
Summary: This study examined the effect of myeloid differentiation primary response gene 88 mutation L265P ( MYD88 L265P ) and/or cluster of differentiation 79B gene mutation Y196 ( CD79B Y196 ) ( MYD88/CD79B ) on central nervous system (CNS) relapse in 270 patients with newly diagnosed diffuse large B‐cell lymphoma (DLBCL). Over a median follow‐up of 6.65 years, 20 patients experienced CNS relapse. Fifty‐five (20%) patients had MYD88/CD79B mutations, and these mutations were significantly associated with an increased risk of CNS relapse in univariable analysis. The overall median time to CNS relapse was 11.5 months, with relapses continuing beyond 2 years in patients harbouring MYD88/CD79B mutations. These patients had 2‐ and 6‐year cumulative CNS relapse rates of 10.9% and 18.1% respectively. Among patients classified as having low or intermediate risk according to the CNS‐International Prognostic Index (CNS‐IPI), those with MYD88/CD79B mutations exhibited higher CNS relapse rates than those without these mutations (18.8% vs. 1.2%). In contrast, patients with high risk showed high CNS relapse, regardless of the mutation status, suggesting heterogeneous mechanisms underlying CNS relapse. In conclusion, the results of this study suggest that MYD88/CD79B mutations may serve as a predictive marker for CNS relapse in DLBCL, although further validation in additional cohorts is warranted.Keywords
Funding Information
- Japan Society for the Promotion of Science (18K19960)
- Japan Society for the Promotion of Science (20K16365)
This publication has 29 references indexed in Scilit:
- Nomogram for predicting survival of patients with diffuse large B-cell lymphomaAnnals of Hematology, 2024
- Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601Annals of Hematology, 2024
- Primary breast diffuse large B‐cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology GroupCancer Medicine, 2023
- Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCLCancer Cell, 2021
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphomaEuropean Journal of Cancer, 2018
- Genetic and Functional Drivers of Diffuse Large B Cell LymphomaCell, 2017
- Genomic characterization of primary central nervous system lymphomaActa Neuropathologica, 2016
- High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesBlood Cancer Journal, 2013
- Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphomaCancer, 2010